Abstract:It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.Supporting tables; 1H NMR, and 13C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">PDF</a>)Molecular formula stings (CSV) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">CSV</a>)Predicted binding mode of 6a in the ATP pocket of JAK2; surface representation of 6a in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">PDB</a>)Predicted binding mode of 15d in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">PDB</a>)Predicted binding mode of 16b in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">PDB</a>)Predicted binding mode of 6a in the active site of HDAC6; surface representation of 6a in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">PDB</a>)Predicted binding mode of 15d in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">PDB</a>)Predicted binding mode of 16b in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">PDB</a>)This article has not yet been cited by other publications.

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6h)-yl)ethyl)benzamide As Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.

Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity

Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents

Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities

Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia

Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity

Synthesis and Biological Evaluation of Thiophene-Based Hydroxamate Derivatives As HDACis with Antitumor Activities

A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells

Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia

Synthesis, Biological Evaluation and Molecular Docking Studies of 3-(1,3-diphenyl-1h-pyrazol-4-yl)-n-phenylacrylamide Derivatives As Inhibitors of HDAC Activity.

Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study

Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity

Synthesis and biological evaluation of ortho-phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases

Design, synthesis and antitumor activity evaluation of novel benzamide HDAC inhibitors

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity

Discovery of ( S )- N -(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6 H )-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate